Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02669706 · ClinicalTrials.gov registry record
Intravenous Pentamidine for Pneumocystis Jirovecii Pneumonia
A clinical trial, sponsored by University of Illinois at Chicago.
- Completed
- Registry status
- 50
- Enrollment target
NCT02669706: Completed study, sponsored by University of Illinois at Chicago.
NCT02669706 is a clinical trial that has completed, run by University of Illinois at Chicago. The registered enrollment target is 50 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02669706 has completed, sponsored by University of Illinois at Chicago.
- COMPLETED
- Registry status
- 50 participants
- Enrollment target
Study Summary
The main objective of this study is to assess the safety of administering intravenous (IV) pentamidine for Pneumocystis jirovecii pneumonia (PJP) prophylaxis in adult inpatients with hematologic malignancies and stem cell transplant recipients. There will also be an assessment of patient satisfaction associated with intravenous pentamidine PJP prophylactic therapy.
Primary Outcome
Safety will be assessed via analyzing the number of patients experiencing adverse effects, with their severity graded using CTCAE v4.0.
Interventions
- DRUG Pentamidine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2015-03 |
| Est. Completion | 2016-06 |
What the finished NCT02669706 record still lists
NCT02669706 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 50 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Pentamidine is the first listed.
NCT02669706 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02669706 about?
NCT02669706 is a clinical study titled "Intravenous Pentamidine for Pneumocystis Jirovecii Pneumonia". The main objective of this study is to assess the safety of administering intravenous (IV) pentamidine for Pneumocystis jirovecii pneumonia (PJP) prophylaxis in adult inpatients with hematologic malignancies and stem cell transplant recipients. There will also be an assessment of patient satisfactio...
What is the current status of trial NCT02669706?
This trial is currently completed. The enrollment target is 50 participants. The study started on 2015-03. Estimated completion is 2016-06.
What interventions are being tested in trial NCT02669706?
The interventions under investigation include: Pentamidine (DRUG).
Who is sponsoring clinical trial NCT02669706?
This trial is sponsored by University of Illinois at Chicago, which has 430 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00200889 · 50 participants · Early Phase 1
Mapping Auricular Vagus Nerve Circuitry
- NCT00409435 · 50 participants · Phase 2
A Study of Pyridostigmine in Postural Tachycardia Syndrome
- NCT01202305 · 50 participants
The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies
- NCT01225913 · 50 participants · Phase 4
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia